Search

Search Constraints

You searched for: Author/Creator Inno, Alessandro

Search Results

2. 18F-Sodium Fluoride PET–CT for the Assessment of Brain Metastasis from Lung Adenocarcinoma. Issue 8 (August 2015)

4. Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation. Issue 2 (19th October 2020)

5. Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation. Issue 2 (19th October 2020)

6. Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation. Issue 2 (19th October 2020)

7. Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation. Issue 2 (19th October 2020)

8. Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation. Issue 2 (19th October 2020)

9. Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation. Issue 2 (19th October 2020)

10. Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation. Issue 2 (19th October 2020)